1 0 ▁years ▁out . ▁▁ ▁Observ ations ▁by ▁S la vin ' s ▁team ▁indicating ▁that ▁re - indu ction ▁of ▁self - tol er ance ▁could ▁be ▁induced ▁by ▁l ym ph o abl ative ▁treatment ▁followed ▁by ▁aut olog ous ▁stem ▁cell ▁trans plant ation ▁provided ▁the ▁r ationale ▁for ▁use ▁of ▁a ▁similar ▁approach ▁for ▁successful ▁treatment ▁of ▁patients ▁with ▁life - th re aten ing ▁auto imm une ▁dis orders ▁including ▁multiple ▁s cl eros is ▁and ▁system ic ▁l up us ▁er yth em atos us . ▁ ▁In ▁ 1 9 7 7 ▁S la vin ▁discovered ▁the ▁first ▁animal ▁model ▁of ▁B - cell ▁le uk emia / ly m ph oma ▁( BC L 1 ) ▁which ▁provided ▁an ▁opportunity ▁to ▁better ▁understand ▁the ▁bi ology ▁of ▁B ▁cells ▁and ▁to ▁develop ▁new ▁th era pe ut ic ▁strateg ies ▁based ▁on ▁the ▁pre cl in ical ▁animal ▁model . ▁ ▁T ogether ▁with ▁Dr . ▁H erman ▁Wald mann , ▁S la vin ▁was ▁the ▁first ▁to ▁introduce ▁the ▁use ▁of ▁an ▁anti - CD 5 2 ▁mon oc l onal ▁ant ib ody ▁( CA MP ATH - 1 ; ▁A lem t uz um ab ▁and ▁currently ▁Lem tr ada ) ▁that ▁was ▁initially ▁used ▁by ▁S la vin ▁for ▁prevent ion ▁of ▁gra ft - vers us - host ▁disease ▁( GV HD ) ▁and ▁subsequently ▁by ▁others ▁for ▁prevent ion ▁and ▁treatment ▁of ▁al log raft ▁re jection ▁and